a b s t r a c t G-protein coupled inwardly rectifying potassium (GIRK) channels are effectors determining degree of analgesia experienced upon opioid receptor activation by endogenous and exogenous opioids. The impact of GIRK-related genetic variation on human pain responses has received little research attention. We used a tag single nucleotide polymorphism (SNP) approach to comprehensively examine pain-related effects of KCNJ3 (GIRK1) and KCNJ6 (GIRK2) gene variation. Forty-one KCNJ3 and 69 KCNJ6 tag SNPs were selected, capturing the known variability in each gene. The primary sample included 311 white patients undergoing total knee arthroplasty in whom postsurgical oral opioid analgesic medication order data were available. Primary sample findings were then replicated in an independent white sample of 63 healthy pain-free individuals and 75 individuals with chronic low back pain (CLBP) who provided data regarding laboratory acute pain responsiveness (ischemic task) and chronic pain intensity and unpleasantness (CLBP only). Univariate quantitative trait analyses in the primary sample revealed that 8 KCNJ6 SNPs were significantly associated with the medication order phenotype (P < .05); overall effects of the KCNJ6 gene (gene set-based analysis) just failed to reach significance (P = .054). No significant KCNJ3 effects were observed. A continuous GIRK Related Risk Score (GRRS) was derived in the primary sample to summarize each individual's number of KCNJ6 ''pain risk'' alleles. This GRRS was applied to the replication sample, which revealed significant associations (P < .05) between higher GRRS values and lower acute pain tolerance and higher CLBP intensity and unpleasantness. Results suggest further exploration of the impact of KCNJ6 genetic variation on pain outcomes is warranted. Ó
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Introduction
Genetic influences on human pain perception and risk for chronic pain are likely to be polygenic [8] . Numerous single nucleotide polymorphisms (SNPs) have been identified in human studies as potential contributors. SNPs in genes encoding for the mu opioid receptor (OPRM1), the beta-2 adrenergic receptor (ADRB2), and catechol-O-methyltransferase (COMT) have all been demonstrated to influence acute pain sensitivity [7, 9, 10 One commonality between OPRM1 and COMT SNPs targeted in prior work is that each can potentially influence the magnitude of opioid inhibition upon activation of opioid receptors by endogenous or exogenous opioid agonists [1, 20, 49] . The degree of opioid inhibition upon receptor activation is also influenced by numerous effectors, including G-protein coupled inwardly rectifying potassium (GIRK) channels of the Kir3.X family [25] [26] [27] . GIRK channels are activated by the b and c subunits of heterotrimeric G i/o proteins after stimulation of opioid receptors by endogenous or exogenous opioids. The ensuing efflux of potassium ions hyperpolarizes the membrane potential, dampens neuronal excitability, and limits nociceptive transmission [14] . Several studies in animals document that both the KCNJ3 (GIRK1) and KCNJ6 (GIRK2) genes can influence pain and opioid analgesic responses [17, 25, 27, 42] . Indeed, the possibility of direct pharmacological manipulation of GIRK channel activity has been suggested as one avenue for developing novel analgesic medications [2, 21, 32, 44] . Surprisingly, human work examining whether GIRK-related genetic variation influences pain responses has been sparse. Only
